MACRINI, SERENA
 Distribuzione geografica
Continente #
NA - Nord America 273
EU - Europa 123
AS - Asia 38
AF - Africa 2
OC - Oceania 1
SA - Sud America 1
Totale 438
Nazione #
US - Stati Uniti d'America 266
IT - Italia 53
SE - Svezia 38
IN - India 15
SG - Singapore 12
CA - Canada 7
BG - Bulgaria 6
CN - Cina 5
DE - Germania 4
UA - Ucraina 4
FR - Francia 3
IE - Irlanda 3
IR - Iran 3
FI - Finlandia 2
GB - Regno Unito 2
HU - Ungheria 2
RO - Romania 2
TG - Togo 2
AR - Argentina 1
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
ES - Italia 1
GR - Grecia 1
JP - Giappone 1
KG - Kirghizistan 1
NL - Olanda 1
Totale 438
Città #
Fairfield 45
Ashburn 23
Chandler 23
Wilmington 19
Cambridge 18
Houston 15
Woodbridge 13
San Paolo di Civitate 12
Rome 11
Seattle 11
Princeton 9
New York 8
Lawrence 7
San Diego 7
Sofia 6
Boston 5
Falls Church 5
Ottawa 5
Andover 4
Millbury 4
Dublin 3
Rizziconi 3
Singapore 3
Ann Arbor 2
Beijing 2
Bühl 2
Catania 2
Imola 2
Lomé 2
Plano 2
Thiene 2
Angoulême 1
Baku 1
Barcelona 1
Bishkek 1
Broomfield 1
Brussels 1
Budapest 1
Cagliari 1
Castelraimondo 1
Codogno 1
Dearborn 1
Des Moines 1
Falkenstein 1
Federal 1
Fremont 1
Gavirate 1
Hebei 1
Hefei 1
Helsinki 1
Jacksonville 1
Lanciano 1
London 1
Norwalk 1
Olinda 1
Pietrasanta 1
Rieti 1
Roseto Degli Abruzzi 1
Segrate 1
Somma 1
Toronto 1
Winnipeg 1
Zanjan 1
Totale 307
Nome #
Evaluation of 5-fluorouracil degradation rate and pharmacogenetic profiling to predict toxicity following adjuvant capecitabine 78
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 59
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 54
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment. A mono-institutional experience 53
null 52
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 41
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 39
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 33
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer. a case report 28
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 27
Molecular basis of drug resistance and insights for new treatment approaches in mCRPC 16
Oligoprogression during Abiraterone therapy treated with radiotherapy in mCRPC patients. 8
Totale 488
Categoria #
all - tutte 1.674
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.674


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201918 0 0 0 0 0 0 0 0 0 0 10 8
2019/202053 7 2 0 2 5 5 7 4 4 4 0 13
2020/202177 6 9 2 1 0 1 3 9 6 2 10 28
2021/2022123 2 1 13 5 13 9 7 8 14 6 29 16
2022/2023120 18 30 12 8 11 17 1 10 7 0 5 1
2023/202484 9 13 1 11 10 16 1 7 0 10 6 0
Totale 488